Table 4.
Incidence Comparison of Some Important All-Grade TRAEs Among Different RET Inhibitors
| Cabozantinib (N = 26), % | Vandetanib (N = 18), % | Lenvatinib (N = 25), % | RXDX-105 (N = 31), % | Pralsetinib (N = 57), % | Selpercatinib (N = 105), % | |
|---|---|---|---|---|---|---|
| Nausea | 31 | 6 | 60 | 8 | Nr | 19 |
| Diarrhea | 62 | 44 | 52 | 18 | Nr | 31 |
| Fatigue | 46 | 11 | 36 | 22 | 15 | 24 |
| Hypertension | 19 | 89 | 68 | Nr | 18 | 29 |
| Neutropenia | Nr | Nr | Nr | Nr | 15 | Nr |
| Elevated ALT | 96 | 6 | 20 | 16 | 17 | 26 |
| Elevated AST | 73 | 6 | 24 | 16 | 22 | 28 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; Nr, not reported. TRAE, treatment-related adverse event.